Skip to content
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share
Download Report

Selected Pharmaceuticals in Development as of April 19, 2022

Oncology

amivantamab / lazertinib

Non Small Cell Lung Cancer
Phase 3

amivantamab / lazertinib

Non Small Cell Lung Cancer 2L
Phase 3

BALVERSA (erdafitinib)

Urothelial cancer
Registration

BALVERSA (erdafitinib)

Non muscle invasive bladder cancer
Phase 2

BALVERSA (erdafitinib)

Tumor Agnostic
Phase 2

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory multiple myeloma
Registration

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI
Phase 3

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory multiple myeloma w/1-3 PL
Phase 3

DARZALEX (daratumumab)

Frontline multiple myeloma transplant eligible (PERSEUS)
Phase 3

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)
Phase 3

DARZALEX (daratumumab)

Smoldering multiple myeloma (SMM3001)
Phase 3

ERLEADA (apalutamide)

High risk prostate cancer (PROTEUS)
Phase 3

ERLEADA (apalutamide)

Localized prostate cancer
Phase 3

IMBRUVICA (ibrutinib)

Pediatric Chronic Graft Versus Host Disease
Registration

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW)
Registration

IMBRUVICA (ibrutinib)

Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)
Registration

IMBRUVICA (ibrutinib)

Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)
Phase 3

IMBRUVICA (ibrutinib)

Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma; (SELENE)
Phase 3

JNJ-1330

Colorectal Cancer
Phase 1

JNJ-4681

Hematological Malignancies
Phase 1

JNJ-6358

Solid Tumors
Phase 1

JNJ-6420

Prostate Cancer
Phase 1

JNJ-6617

Hematological Malignancies
Phase 1

JNJ-6633

Hematological Malignancies
Phase 1

JNJ-6665

Hematological Malignancies
Phase 1

JNJ-8343

Prostate Cancer
Phase 1

JNJ-8780

Hematological Malignancies
Phase 1

JNJ-8902

Prostate Cancer
Phase 1

JNJ-9414

Prostate Cancer
Phase 1

niraparib

L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone
Phase 3

niraparib / abiraterone acetate

M1 Metastatic Castration-Sensitive Prostate Cancer in combination with abiraterone acetate and Prednisone
Phase 3

RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy
Phase 3

talquetamab (GPRC5D/CD3)

Relapsed refractory multiple myeloma
Phase 2

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non-muscle invasive bladder cancer
Phase 3

TAR-200 (RIS/gemcitabine plus cetrelimab)

Muscle non invasive bladder cancer
Phase 2

teclistamab (BCMA/CD3)

Relapsed refractory multiple myeloma
Registration

teclistamab (BCMA/CD3)

Multiple Myeloma 1-3PLs
Phase 3
This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; aprocitentan: Idorsia; X-Linked Retinitis Pigmentosa (AAV-RPGR) and Achromatopsia Gene Therapies (CNGA3 and CNGB3): MeiraGTx; JNJ-7100: Exonate; JNJ-1887: Hemera Biosciences; PNPLA3: Arrowhead Pharmaceuticals; COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZCOBIX / REZOLSTA FDC: Gilead Sciences; JULUCA and Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; COVID-19 vaccine: funded in part with federal funds from the U.S. Department of Health and Human Services; JNJ-3989: Arrowhead Pharmaceuticals; bacteriophage products using recombinant CRISPR/Cas3 Phage platform: Locus Biosciences; Cloudbreak antiviral conjugates (AVCs) including CD388: Cidara Therapeutics; Janssen's HIV vaccine program: IPCAVD, MHRP, HJF, the Ragon Institute, IAVI, Bill & Melinda Gates Foundation, NIAID, U.S. Military HIV Research Program, U.S. Army Medical Materiel Development Activity, MIT, Harvard, HVTN, SAMRC, Bavarian Nordic; Zika vaccine: Beth Israel Deaconess Medical Center (Harvard Medical School); ExPEC: GSK; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113, JNJ-4238 and JNJ-5186: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; VELCADE: Millennium, The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO; Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Sload Kettering; cilta-cel: Legend Biotech; niraparib: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); Janssen's Monovalent Ebola Vaccine: Bavarian Nordic A/S, NIAID, IMI2, EFPIA, BARDA, NIH; Filovirus multivalent vaccine: Bavarian Nordic
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue